GLIX yields 1.68% · JNJ yields 2.14%● Live data
📍 JNJ pulled ahead of the other in Year 7
Combined, GLIX + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GLIX + JNJ for your $10,000?
GLIX seeks to generate alpha from the long-term growth trends of global infrastructure development and modernization. The fund primarily invests in large-cap companies that derive over 50% of their revenues or assets from infrastructure activities. These activities include water treatment, generation and distribution of energy and resources, communication and media services, as well as the development or operation of infrastructure such as pipelines, roads, airports, railroads, and ports. Security selection focuses on monopolistic businesses that deliver stable long-term cash flows with inflation-linked revenues and lower volatility than the broader equity market. The portfolio consists of 25-50 preferred infrastructure companies. GLIX offers global diversification, including exposure to emerging markets. Currency risk is hedged through foreign currency forward contracts to reduce volatility against the US dollar. The fund may also utilize repurchase agreements and money market instruments.
Full GLIX Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.